Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM).
Naveen S VasudevGemma AinsworthSarah R BrownLisa M PickeringTom WaddellKate FifeRichard GriffithsAnand SharmaEszter KatonaHelen HowardGalina VelikovaAnthony MaraveyasJanet BrownCarmel PezaroMark TuthillEkaterini BoletiAmit BahlBernadett SzabadosRosamonde E BanksJoanne BrownBalaji VenugopalPoulam Manubhai PatelAnkit JainStefan N SymeonidesPaul D NathanFiona J CollinsonThomas PowlesPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Rates of grade 3-5 trAEs were significantly lower in patients receiving modified versus standard IPI. Although 12-month PFS did not meet the prespecified efficacy threshold compared with historical control, informal comparison of treatment groups did not suggest any reduction in efficacy with the modified schedule.